|  |
| --- |
| Pancreas Case 1 Answer sheet |
| Tumor Information |
| Primary Site | C25.1 |
| Histology | 8452/3 |
| Clinical Grade | 9 |
| Pathological Grade | 9 |
|  Tumor Size Summary | 027 (at resection) |
| Summary Stage 2018 | 1 (localized) |
|  AJCC Clinical Staging | cT2 cN0 cM0 Stage 1B33 mm primary tumor, no nodes or mets |
|  AJCC Pathological Staging | pT2 pN0 cM0 Stage IB2.7 cm primary tumor, 0/19 nodes |
| RLN Examined | 19 |
| RLN Positive | 00 |
| CA 19-9 Pretreatment Lab Value | XXXX.9 |
| EOD Primary Tumor | 100 |
| EOD Nodes | 000 |
| EOD Mets | 00 |

|  |
| --- |
| Treatment |
| Diagnostic/Staging Procedure | 02 |
| Surgery of Primary Site | A300 Partial pancreatectomy, NOS; example: distal  |
| Scope of RLN Surgery | 5 |
| Surgery Other Reg/Dis Sites | 2 |
| Radiation | None |
| Chemotherapy | None |
| Immunotherapy | None |
| Hormone Therapy | None |
|  |  |
| Systemic/Surgery Sequence | 0 |
| Surg Approach 2010 | 3 (laparoscopic) |
| Radiation Surgery Sequence | 0 |
|  |  |
|  |  |
|  |  |

|  |
| --- |
| Pancreas Case 2 Answer sheet |
| Tumor Information |
| Primary Site | C25.0 Head |
| Histology | 8140/3 Adenocarcinoma |
| Clinical Grade | 3 PD |
| Pathological Grade | 9 |
|  Tumor Size Summary | 037 |
| Summary Stage 2018 | 2 Abuts Major Vein |
|  AJCC Clinical Staging | cT2 cN0 cM0 Stage IBPrimary tumor 3.7 cm, no nodes or mets |
|  AJCC Pathological Staging | Blank |
| RLN Examined | 00 |
| RLN Positive | 98 |
| CA 19-9 Pretreatment Lab Value | 795.0 |
| EOD Primary Tumor | 500 (superior mesenteric vein) |
| EOD Nodes | 000 |
| EOD Mets | 00 |

|  |
| --- |
| Radiation |
| Phases | I |
| Primary Treatment Volume | 58 (pancreas) |
| Draining Lymph Nodes | 00 (none) |
| Treatment Modality | 02 (photons 6X) |
| External Beam Planning Technique | 10 An external beam technique in which the treatment plan is adapted over the course of radiation to reflect changes in the patient’s tumor or normal anatomy radiation using an MRI scan obtained at the treatment machine (online). These approaches are sometimes described as MR-guided online re-optimization or online re- planning. If a treatment technique is described as both MR-guided online adaptive therapy as well as another external beam technique (IMRT, SBRT, etc.), then it should be categorized as MR-guided online adaptive therapy. If a treatment is described as “adaptive” but does not include the descriptor “online”, this code should not be used. Clinic notes may refer to an MR-Linac or the brand name of an MR-Linac called MRIidian or Unity.  |
| Dose Per Fraction (cGy) | 01000 |
| Number of Fractions | 005 |
| Total Dose (cGy) | 005000 |
| # of Phases of RT to this Volume | 01 |
| RT Discontinued Early | 01 |
| Total Dose | 005000 |
| Radiation/Surgery Sequence | 00 |
| Reason for No Radiation | 0 |
|  |  |
|  |  |

|  |
| --- |
| Systemic Therapy |
| Chemotherapy | 03 (FOLFIRINOX) |
| Hormone Therapy | 00 |
| Immunotherapy | 00 |
| Hematologic Transplant and Endocrine Procedures | 00 |
| Systemic/Surgery Sequence | 00 |
| Mets to liver would be progression. |  |

|  |
| --- |
| Pancreas Case 3 Answer sheet  |
| Tumor Information |
| Primary Site | C25.2 |
| Histology | 8249/3 (WD NET grade 3/3) |
| Clinical Grade | 9 (biopsy from the liver) |
| Pathological Grade | 9 |
|  Tumor Size Summary | 054 |
| Summary Stage 2018 | 7 |
|  AJCC Clinical Staging | cT3 cN0 pM1a Stage 4Limited to the pancreas, 5.7 cm, no nodes, histologic confirmation of liver mets. |
|  AJCC Pathological Staging | cT3 cN0 pM1a Stage 4Limited to the pancreas, 5.7 cm, no nodes, histologic confirmation of liver mets.\*\*See AJCC page 22 – if you have histologic confirmation of distant mets during the diagnostic workup, then your clinical and path staging are identical. |
| RLN Examined | 00 |
| RLN Positive | 98 |
| Ki-67 | XXX.9 (Ki-67 is from liver bx) |
| EOD primary tumor | 100 |
| EOD Nodes | 000 |
| EOD Mets | 10 (liver) |

|  |
| --- |
| Radiation |
| No radiation therapy |  |  |  |

|  |
| --- |
| Systemic Therapy |
| Chemotherapy | 03 (capecitabine and temozolomide) |
| Hormone Therapy | 00 |
| Immunotherapy | 00 |
| Hematologic Transplant and Endocrine Procedures | 00 |
| Systemic/Surgery Sequence | 00 |